Evidence map›Paper›PMID 35180109›Full record

ArticleJournal of Alzheimer's disease : JAD2022

Validity of the Web-Based, Self-Directed, NeuroCognitive Performance Test in Mild Cognitive Impairment.

P Murali Doraiswamy, Terry E Goldberg, Min Qian, Alexandra R Linares, Adaora Nwosu, Izael Nino, Jessica D'Antonio, Julia Phillips, Charlie Ndouli, Caroline Hellegers and 5 more

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

P Murali DoraiswamyNeurocognitive Disorders Program, Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA.
Terry E GoldbergDepartment of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute, New York, NY, USA.
Min QianDepartment of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA.
Alexandra R LinaresNeurocognitive Disorders Program, Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA.
Adaora NwosuNeurocognitive Disorders Program, Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA.
Izael NinoDepartment of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute, New York, NY, USA.
Jessica D'AntonioDepartment of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute, New York, NY, USA.
Julia PhillipsDepartment of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute, New York, NY, USA.
Charlie NdouliDepartment of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute, New York, NY, USA.
Caroline HellegersNeurocognitive Disorders Program, Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA.
Andrew M MichaelDuke Institute for Brain Sciences, Durham, NC, USA.
Jeffrey R PetrellaDepartment of Radiology, Duke University Medical Center, Durham, NC, USA.
Howard AndrewsDepartment of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA.
Joel SneedDepartment of Psychology, Queens College, City University of New York, Flushing, NY, USA.
Davangere P DevanandDepartment of Psychiatry, Columbia University Medical Center, and the New York State Psychiatry Institute, New York, NY, USA.
Columbia University Irving Medical Center · USDuke University · USDuke Medical Center · USQueens College, CUNY · US

Funding

Novel Cognitive and Functional Measures for Alzheimer's Disease Prevention Trials: Sensitivity to BiomarkersR01AG051346 · NIA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI GOLDBERG, TERRY, HARVEY, PHILIP D. · 2018 to 2022
$9.8M
COGNITIVE TRAINING AND NEUROPLASTICY IN MILD COGNITIVE IMPAIRMENTR01AG052440 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DAVANGERE P DEVANAND · 2017 to 2026
$9.3M
NIA NIH HHS R01 AG051346NIA NIH HHS R01 AG052440
6 · The paper itself

Abstract

backgroundDigital cognitive tests offer several potential advantages over established paper-pencil tests but have not yet been fully evaluated for the clinical evaluation of mild cognitive impairment.

objectiveThe NeuroCognitive Performance Test (NCPT) is a web-based, self-directed, modular battery intended for repeated assessments of multiple cognitive domains. Our objective was to examine its relationship with the Alzheimer's Disease Assessment Scale-Cognition Subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) as well as with established paper-pencil tests of cognition and daily functioning in mild cognitive impairment (MCI).

methodsWe used Spearman correlations, regressions and principal components analysis followed by a factor analysis (varimax rotated) to examine our objectives.

resultsIn MCI subjects, the NCPT composite is significantly correlated with both a composite measure of established tests (r = 0.78, p < 0.0001) as well as with the ADAS-Cog (r = -0.55, p < 0.0001). Both NCPT and paper-pencil test batteries had a similar factor structure that included a large "g" component with a high eigenvalue. The correlation for the analogous tests (e.g., Trails A and B, learning memory tests) were significant (p < 0.0001). Further, both the NCPT and established tests significantly (p < 0.0001) predicted the University of California San Diego Performance-Based Skills Assessment and Functional Activities Questionnaire, measures of daily functioning.

conclusionThe NCPT, a web-based, self-directed, computerized test, shows high concurrent validity with established tests and hence offers promise for use as a research or clinical tool in MCI. Despite limitations such as a relatively small sample, absence of control group and cross-sectional nature, these findings are consistent with the growing literature on the promise of self-directed, web-based cognitive assessments for MCI.

Indexed as

Alzheimer DiseaseCognitive DysfunctionCross-Sectional StudiesHumansInternetNeuropsychological TestsAlzheimer’s diseaseclinical trialscomputerized cognitive testsneurocognitive performance test

Identifiers

PMID35180109
PMCPMC13431147
OpenAlexW4213094294

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.